Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 6Neoplasms 5Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Carcinosarcoma 1Neoplasms, Second Primary 1Locally Advanced Rectal Cancer (LARC) 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Cisplatin 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10Paclitaxel 6Platinum 5Cyclophosphamide 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 4durvalumab 4cemiplimab 4Radiotherapy, Intensity-Modulated 4Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Fluorouracil 3Cetuximab 3Carboplatin 3Biopsy 3poly ICLC 2fludarabine phosphate 2cabozantinib 2atezolizumab 2Radiation 2Ipilimumab 2Interviews as Topic 2Heavy Ion Radiotherapy 2Gemcitabine 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma × dostarlimab × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡